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Abstract
Despite chronic inflammation, psoriatic lesions hardly ever progress to skin cancer. Aberrant function of the CCHCR1 gene
(Coiled-Coil a-Helical Rod protein 1, HCR) within the PSORS1 locus may contribute to the onset of psoriasis. As CCHCR1 is
expressed in certain cancers and regulates keratinocyte (KC) proliferation in a transgenic mouse model, we studied its
relation to proliferation in cutaneous squamous cell cancer (SCC) cell lines by expression arrays and quantitative RT-PCR and
in skin tumors by immunohistochemistry. CCHCR1 protein was detected in the pushing border of SCC and lining basal cell
carcinoma islands. Different from psoriasis, Ki67 had a similar expression pattern as CCHCR1. The most intense CCHCR1
staining occurred in areas positive for epidermal growth factor receptor (EGFR). Expression of CCHCR1 mRNA was
upregulated 30–80% in SCC lines when compared to normal KCs and correlated positively with Ki67 expression. The most
aggressive and invasive tumor cell lines (RT3, FaDu) expressed CCHCR1 mRNA less than non-tumorigenic HaCaT cells.
Moreover, the tumor promoters okadaic acid and menadione downregulated CCHCR1 mRNA. We conclude that both in
psoriasis and the early stages of KC transformation, CCHCR1 may function as a negative regulator of proliferation, but
beyond a certain point in oncogenesis cannot control this phenomenon any longer.
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Introduction
We have previously shown that the CCHCR1 gene within the
major psoriasis susceptibility locus PSORS1 may function as a
negative regulator of KC proliferation [1–3]. The CCHCR1 gene
encodes a 782 amino acid protein (GenBank AY029160) [4] that is
differently expressed in lesional psoriatic skin compared to normal
skin: lesionally CCHCR1 locates in basal and suprabasal KCs
where the epidermis is at its thinnest. Staining for the cell
proliferation marker Ki67 shows inverse correlation to CCHCR1
in psoriasis lesions, consistent with a role in KC proliferation
[1,4]. Furthermore, our mouse model overexpressing the
CCHCR1*WWCC psoriasis risk allele under keratin 14 promoter
shows impaired proliferation capability of KCs [3], suggesting less
active activator protein 1 (AP-1) mediated signaling in the risk
mice. AP-1 mediated signaling regulates genes associated with cell
proliferation, including EGFR also known as ErbB1 [5].
Psoriasis lesions hardly ever progress to skin cancer despite
chronic inflammation that often is a risk factor for cancer [6,7].
Both psoriasis and skin cancer are characterized by uncontrolled
KC proliferation in addition to angiogenesis and inflammation.
Cellular proliferation and differentiation can be mediated via
EGFR signaling [8]. Multiple EGFR ligands (TGF-a, amphir-
egulin, heparin-binding EGF-like growth factor) are overexpressed
in psoriasis lesions, and transgenic expression of the human
amphiregulin gene induces a psoriasis-like phenotype [8]. EGFR
signaling has also been implicated in the pathogenesis of non-
melanoma skin cancer [8–10]. Interestingly, both improvement
and exacerbation of psoriasis have been reported in association
with EGFR tyrosine kinase inhibitor cancer treatment [11,12].
In our previous studies, CCHCR1 expression was detected in
nonproliferating cells in breast and lung adenocarcinomas: the
hyperproliferation marker Ki67 was detected in adjacent, but not
in the same cells as CCHCR1 [1]. Furthermore, EGF up-
regulated CCHCR1 protein expression in HaCaT cells [2]. To
further understand the function of CCHCR1 in KC transforma-
tion and skin cancer, we studied its expression in premalignant and
malignant squamous lesions and basal cell carcinoma (BCC). As
EGFR and its downstream target cyclin-D1 are involved in cancer
development and possibly affected by the putative CCHCR1
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6030pathways, we examined their expression in comparison to
CCHCR1. The relation of CCHCR1 to KC hyperproliferation
was highlighted by staining adjacent samples with the Ki67
antibody. We also studied the correlation of CCHCR1 expression
level to those of Ki67 and EGFR in cultures of cells with different
proliferative and invasive characteristics. CCHCR1 mRNA levels
were determined in HaCaT cultures incubated with diverse
bioactive agents with importance in tumor promotion, oxidative
stress or psoriatic inflammation. Finally, the expression levels of
CCHCR1, Ki67, and EGFR mRNAs were determined in an
oligonucleotide microarray of cutaneous SCC cell lines and
normal human epidermal KC cell lines. Our results suggest that
CCHCR1 is expressed in non-melanoma skin cancers in
association with EGFR and Ki67 in vivo. However, in cell culture
the most atypic cells express CCHCR1 less than immortalized
HaCaT cells, and tumor promotion and induced proliferation of
HaCaT cells correlates with reduced CCHCR1 expression.
Results
CCHCR1 is expressed in SCC in association with EGFR,
cyclin-D1, and Ki67
To study the role of CCHCR1 in KC proliferation and
transformation, we investigated CCHCR1 protein expression by
immunohistochemistry in different skin tumors in relation to
EGFR, its downstream target cyclin-D1, and the hyperprolifera-
tion marker Ki67. CCHCR1 positive cells were present in 20/22
SCCs studied. Proliferative cancer cells at the invasive front
expressed CCHCR1 (Figure 1A,D,G,S1; Figure 2A,C,E), whereas
the cohesive cancer cells in the middle were CCHCR1 negative.
Infiltrative outgrowth was typical of CCHCR1 positive areas,
however, the atypic cells were heterogenous for CCHCR1
expression (Figure 2A). CCHCR1 expression in SCC was
associated with positive EGFR staining in all specimens
(Figure 1A,C,D,F). The CCHCR1 positive cancer nests in the
lower dermis were cyclin-D1 positive as well (Figure 2C–F). Cells
positive for the hyperproliferation marker Ki67 were located
mostly in the same areas as CCHCR1 positive cells (Figure 1B,E;
2B). However, in grade III SCCs Ki67 was more abundantly
present also in cohesive tumor areas that were devoid of CCHCR1
expression (data not shown). For comparison, a normal skin
sample is shown with basal KCs positive for CCHCR1 and
EGFR, and scattered positivity for Ki67 (Figure 1H–J).
CCHCR1 is expressed by the palisading cancer cells in
BCC
In BCC, CCHCR1 was expressed especially in the cytoplasm of
the palisading cancer cells of the well-defined carcinoma islands
(Figure 3A,C). Three out of 15 BCC specimens were sclerosing,
but CCHCR1 was not more abundant in them (data not shown).
CCHCR1 was expressed in a granular pattern in seven samples
(Figure 3A,C) co-localizing with EGFR (Figure 3B,D). All five
samples studied were cyclin-D1 positive: however, its expression
was not as strong as that of CCHCR1 and more concentrated to
the centre of the tumor nests (data not shown). Cytoplasmic
expression of CCHCR1 in basal KCs in normal looking skin
adjacent to the BCC area varied between samples. EGFR
expression was higher in basal KCs of normal skin than in
palisading cells in most of the samples.
To study whether CCHCR1 and EGFR co-localize also at the
cellular level, we transiently transfected HaCaT cells with a
CCHCR1 construct and visualized CCHCR1 and EGFR
expression with immunofluorescence. CCHCR1 expression was
detected as a ring-like, cytoplasmic pattern, while EGFR
expression was more or less membrane bound and did not co-
localize with CCHCR1 staining (Figure 4A–D). Transfected and
non-transfected cells showed similar EGFR expression, suggesting
that CCHCR1 does not influence EGFR expression or localiza-
tion (Figure 4B).
CCHCR1 expression in keratoacanthomas is associated
with lymphocyte infiltration
Keratoacanthoma (KA), histologically a malignant neoplasm
but behaving in a benign manner, is often considered a
‘‘precursor’’ lesion to SCC. KAs generally showed positive
CCHCR1 staining especially in KCs of the pushing border in
areas with a prominent lymphocyte infiltrate surrounding the
tumor (Figure 5A,C). EGFR-positive cells were present in the
same areas in the studied samples (Figure 5B,D). In the CCHCR1
positive area, Ki67 expression was also encountered in all three
samples, but with less intensity than in SCCs (Figure 5E,F).
Bowen’s disease and actinic keratoses express CCHCR1 in
spongiotic and inflammatory areas
Spongiosis, inflammatory infiltrate, and capillary proliferation
were associated with CCHCR1 expression in 11/21 Bowen’s
disease (SCC in situ) samples (Figure 6A,B). Areas lacking
inflammation and spongiosis expressed less CCHCR1
(Figure 6C), neither was CCHCR1 expression associated with
KC atypia. In Bowen’s disease, cytoplasmic CCHCR1 staining
was encountered basally and suprabasally in dermal papillae
(Figure 6B) resembling CCHCR1 staining of psoriatic lesional skin
(Figure 6E), especially in hypertrophic samples. Also EGFR
expression in Bowen’s disease resembled the expression pattern of
CCHCR1 (Figure 6D). In psoriasis, CCHCR1 expression was
most intense in areas with less Ki67 positive KCs (Figure 6F).
Eight of 11 studied actinic keratosis (AK) specimens had
CCHCR1 positive basal or suprabasal KCs (Figure 6G).
CCHCR1 positive cells were often encountered in regions with
spongiosis or inflammation.
Expression of CCHCR1 is up-regulated and correlates
with Ki67 expression in cutaneous SCC cell lines
Next, we compared the mRNA expression profiles of
CCHCR1, EGFR, Ki67, and cyclin-D1 in different cutaneous
SCC cell lines (five primary and three metastatic), by performing
Affymetrix experiments. The oligonucleotide microarray based
expression profile showed that CCHCR1 gene is expressed in
SCC cells (Figure 7A). Signal levels of the CCHCR1 probe sets
were up to 80% higher in the cutaneous SCC cell lines (n=8) than
in the normal human epidermal KCs (n=5), but there were no
marked differences in CCHCR1 expression levels between
primary and metastatic SCC lines. Expression levels in the SCC
cell lines were variable, but the average levels showed a slight
increase (of 30%; p.0.05) when compared to normal KCs by
quantitative real-time RT-PCR (TaqMan) (Figure 7C). Signal
levels of the Ki67 probe sets were 3–4 fold higher in SCC cell lines
than in normal epidermal KCs (Figure 7A). This observation was
also confirmed by TaqMan PCR (Figure 7D). Importantly,
expression levels of CCHCR1 correlated with the levels of Ki67
in the microarray data (Figure 7B). A slight correlation (R=0.46)
between the CCHCR1 and Ki67 mRNA levels was observed in
the TaqMan data as well (Figure 7E). The expression levels of
EGFR mRNA in the SCC cell lines were between 80% and 180%
of the normal KC expression levels in 4 of 8 probe sets (Figure 7A).
Both cyclin-D1 probe sets were present in all cell lines and the
mean signal levels were up to 60% higher in the SCC cell lines as
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PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e6030Figure 1. CCHCR1, Ki67, and EGFR are coexpressed in grade I SCC and in normal skin. Serial sections of grade I SCC (A–C) and normal skin
(H–J) were immunostained with antibodies against CCHCR1, Ki67, and EGFR. Higher magnifications of A–C are also shown (D–F, respectively).
CCHCR1 staining (G) in an adjacent section to EGFR staining (F). CCHCR1 protein (A) is expressed in proliferative cancer cells at the invasive front of
dermal cancer cell islands of an SCC in association with the hyperproliferation marker Ki67 (B) and EGFR (C). The Ki67 positive cells (E) express CCHCR1
(D). EGFR staining (F) associates with CCHCR1 staining (G) in adjacent sections. Normal skin samples express CCHCR1 (H) and EGFR (J) in basal KCs,
while Ki67 expression (I) is more sparse. Arrows point at illustrative positions. Scale bars: (A–C) 50 mm; (D–G) 12.5 mm; (H–J) 25 mm.
doi:10.1371/journal.pone.0006030.g001
CCHCR1 in Skin Cancer
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e6030Figure 2. Heterogeneous expression of CCHCR1, Ki67, and cyclin D1 in grade III and II SCCs. Serial sections of grade III (A, B) and grade II
(C, D) SCC were stained with the indicated antibodies. Higher magnification of another grade II SCC (E, F). In grade III SCC (A, B), expression of CCHCR1
is heterogeneous: many, but not all, cancer cells express both CCHCR1 (A) and Ki67 (B). The insets show lower magnification of the same region,
asterisk points out a cancer cell with negative CCHCR1 and Ki67 expression. In grade II SCC (C, D), infiltrative outgrowth is CCHCR1 positive (C), and
the CCHCR1 positive cancer nests are also cyclin-D1 positive (D). Adjacent sections of grade II SCC (E, F) show association of CCHCR1 and cyclin-D1
positive cells. Arrows indicate corresponding areas. Scale bars: (A,B,E,F) 12.5 mm; (C,D, insets) 50 mm.
doi:10.1371/journal.pone.0006030.g002
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correlation with the EGFR expression level, but no
correlation between CCHCR1 and cyclin-D1 was detected (data
not shown).
Okadaic acid and menadione downregulate CCHCR1
mRNA expression in HaCaT cells
In order to determine whether different bioactive agents alter
CCHCR1 mRNA expression, we treated HaCaT cell cultures
with tumor promoters, oxidative stress inducers, and agents
involved in psoriatic inflammation. Okadaic acid (OA) and
menadione, both compounds shown to promote tumors in vivo
and induce oxidative stress, downregulated CCHCR1 mRNA
levels in HaCaT cells up to 10-fold with increasing dose (OA) and
3-fold (menadione) (Figure 8A). EGFR and Ki67 mRNA levels of
OA and menadione treated HaCaT cells were downregulated as
well (Figure 8B,C). Menadione or OA treatments did not
essentially alter expression of the house-keeping gene GAPDH
in HaCaT cells, suggesting that these agents did not affect viability
of the cells. The tumor promoters 12-phorbol-13-myristate-acetate
(PMA) and staurosporine or the anti-estrogen tamoxifen, H2O2
producing oxidative stress, leptin, IL-6 or staphylococcal endo-
toxin B, activin or anisomycin, did not significantly influence
CCHCR1 mRNA levels (data not shown).
CCHCR1 is downregulated in the most aggressive tumor
cell lines
To further study the role of CCHCR1 in KC transformation,
we compared CCHCR1 mRNA expression in cell lines with
different metastatic and invasive properties. Based on quantitative
TaqMan RT-PCR, CCHCR1 and Ki67 expression levels were
similar in immortalized HaCaT and tumorigenic A5 ras-
transformed cell lines (Figure 8D,E). However, with ascending
tumorigenicity in ras-transformation, invasive II4 and metastatic
RT3 cells expressed less CCHCR1 mRNA, and this trend was also
seen with malignant A431 cells (Figure 8D). Similarly, FaDu cells
that are more invasive than HaCaT and A431 cells [13] expressed
less CCHCR1, Ki67, and EGFR (Figure 8D–F). Also Ki67 and
EGFR expression diminished with ras-transformation
(Figure 8E,F). Interestingly, A431 cells were the only cells to
express EGFR significantly more than HaCaT cells (Figure 8F),
Ki67 and CCHCR1 expression remaining at a lower level
(Figure 8D,E).
CCHCR1 mRNA expression is downregulated when
keratinocytes are in a rapidly proliferating state
To study CCHCR1 mRNA expression in immortal but non-
tumorigenic HaCaT cells of different proliferative stages, we
performed cell culture experiments according to the strategy of
Figure 3. CCHCR1 and EGFR colocalize in BCC. Serial sections of BCC (A, B) were stained with antibodies against CCHCR1 and EGFR. Higher
magnifications of A and B are also shown (C, D, respectively). CCHCR1 protein is expressed in a granular pattern in the cytoplasm of the palisading
cancer cells of a nodular BCC (A, C). CCHCR1 expression (C) co-localizes with EGFR staining (D). CCHCR1 and EGFR are also expressed in basal KCs (A,
B). Arrows show corresponding positions. Scale bars: (A,B) 50 mm; (C,D) 25 mm.
doi:10.1371/journal.pone.0006030.g003
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(controls) and confluent cells after a 1-wk starving period (cells
forced to quiescence) expressed CCHCR1 more than HaCaT cells
stimulated to proliferate by addition of serum to a non-confluent
subculture (Figure 9A). CCHCR1 expression decreased especially
during the first four days. The proliferation status of the cells (as
confirmed by Ki67 mRNA expression) correlated negatively with
CCHCR1 expression (Figure 9B): decrease in CCHCR1 expres-
sion was associated with increase in Ki67 expression. As the cells
reattained confluency, the expression of CCHCR1 increased again
to the original level (Figure 9A). One of the four experiments was
done using even lower numbers of cells. Here we demonstrated an
intense proliferation during the first time points (24 h and 48 h) as
relative Ki67 mRNA expression increased 6-fold compared to
control cells (two sets of control cells giving the two values around
value 1). The negative correlation of CCHCR1 expression with
Ki67 expression was even more profound as relative CCHCR1
mRNA at the same time decreased near to zero from the two
control cell values around value 1 (Figure 9D). Interestingly,
EGFR mRNA levels followed the CCHCR1 expression pattern
rather than Ki67 expression pattern (Figure 9C,E). By forcing
HaCaT cells to differentiate with high-calcium medium, the
expression of CCHCR1 remained unaltered as measured with
TaqMan PCR (data not shown), agreeing with our previous data
that CCHCR1 mRNA levels were non-altered in differentiated
normal KCs [1]. Involucrin was used as a differentiation marker to
confirm the differentiation status of the HaCaT cells upon calcium
administration [15].
Discussion
Our results presented here show that CCHCR1, a candidate
gene for psoriasis, was expressed in the majority of SCCs, BCCs
and KAs studied, suggesting that CCHCR1 may have a role not
only in KC proliferation but also in transformation. EGFR
expression correlated with CCHCR1 expression, and cyclin-D1, a
downstream target of EGFR and a positive regulator of cell cycle
progression [16], was also found expressed in the same areas. In
normal epidermis, both EGFR and CCHCR1 are expressed
basally [4,8] (Figure 1). Expression of EGFR, ‘‘a survival factor for
tumor cells’’, is even considered to be necessary to maintain KCs
in a proliferative state [8]. We postulate that EGFR may regulate
CCHCR1 expression as we have recently demonstrated that EGF
stimulation upregulates CCHCR1 protein expression [2]. Our
experiments here with transfected HaCaT cells suggested that
overexpression of CCHCR1 does not regulate EGFR expression.
According to our findings, transformed KCs have a different
CCHCR1 status in correlation to the hyperproliferation marker
Ki67 status as compared with non-tumorigenic KCs. Distinct from
the benign hyperproliferative disorder psoriasis ([1]; Figure 6E–F),
expression of the hyperproliferation marker Ki67 was demon-
strated here in the same areas as CCHCR1 expression at the
Figure 4. Immunofluorescence staining of HaCaT cells for CCHCR1 and EGFR. CCHCR1 transfected HaCaT cells (A–D) stained with
antibodies against CCHCR1 (A) and EGFR (B). Overlay of A and B is shown in (C), and DAPI staining showing nuclei in (D). Cells expressing CCHCR1
(green) were also positive for EGFR (red) but the two proteins did not co-localize (C). CCHCR1 positive (arrow) and negative (arrow head) cells exhibit
similar EGFR expression suggesting that CCHCR1 overexpression does not affect EGFR expression (B).
doi:10.1371/journal.pone.0006030.g004
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PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e6030Figure 5. Expression of CCHCR1, EGFR, and Ki67 in keratoacanthoma. Serial sections of KA (A, B, E, F) were stained with the antibodies
against CCHCR1 and EGFR (A, B) or against CCHCR1 and Ki67 (E, F). Higher magnifications of A and B are shown (C, D, respectively). The pushing
border of a KA is CCHCR1 positive (A) co-localizing with EGFR (B). Another sample is shown (E) with a prominent lymphocyte infiltrate and
cytoplasmic CCHCR1 expression of the pushing border cells. More scarce Ki67 expression (F) is defined to the same areas but not necessarily to the
same cells. Arrows indicate corresponding positions. Scale bars: (A, B, E, F) 50 mm; (C, D) 12.5 mm.
doi:10.1371/journal.pone.0006030.g005
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e6030Figure 6. Expression of CCHCR1 in Bowen’s disease, psoriasis, and actinic keratosis. Sections of Bowen’s disease (A–D) immunostained
with antibodies against CCHCR1 and EGFR as indicated. Serial sections of psoriasis (E, F) were stained with antibodies for CCHCR1 and Ki67. AK
samples (G, H) were stained with CCHCR1 antibodies. In Bowen’s disease (A, B), spongiosis, inflammatory infiltrate, and capillary proliferation are
associated with CCHCR1 expression while areas lacking inflammation and spongiosis express less CCHCR1 (C). EGFR expression (D) in basal and
suprabasal KCs of dermal papillae associates with CCHCR1 expression (B). Also in psoriasis (E), CCHCR1 is expressed basally or suprabasally (arrows)
overlying the dermal papillae (dp) while rete ridges (rr) projecting into the dermis are almost negative for CCHCR1. In contrast, Ki67 expression (F)
localizes to regions that are almost negative for CCHCR1 cells (arrowheads). AK samples (G) express CCHCR1 basally and suprabasally in association
with KC heterogeneity, spongiosis or inflammation but adjacent areas with less inflammation or spongiosis (H) stain only faintly. Scale bars: (A–D)
50 mm; (E, F) 25 mm; (G, H) 12.5 mm.
doi:10.1371/journal.pone.0006030.g006
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and lung adenocarcinomas, CCHCR1 positive cells are Ki67
negative [1] but this discrepancy may be due to differences
between adenocarcinoma and SCC cells or the site organ of
cancer. The positive correlation with CCHCR1 and Ki67
expression in skin cancers was supported by the expression
profiling of cutaneous SCC cell lines. However, there was negative
correlation with CCHCR1 and EGFR expression in these same
cell lines as well as in invasive FaDu tumor cells [17], suggesting
that EGFR transcription was inhibited. However, this might
reflect different EGFR variants studied, since the specific probe for
variant 2 seemed to be more downregulated than variant 1 or
probes recognizing all variants.
Despite positive CCHCR1 and Ki67 expression in vivo in skin
cancer and in Affymetrix assay of SCC cell lines, we show that
CCHCR1 and Ki67 mRNAs are downregulated in cultured cells
with ascending transformation and also in non-tumorigenic
HaCaT cells treated with compounds that promote tumors in
vivo. Metastatic RT3 and invasive II4 cells expressed CCHCR1
and Ki67 less than tumorigenic A5 and immortalized HaCaT
cells, suggesting that CCHCR1 and Ki67 expression increases
inversely to the level of ras-transformation. Similarly, EGFR
expression was downregulated in all ras-transformed cells, even in
A5 cells. CCHCR1 mRNA was also diminished in the invasive
FaDu cells compared to A431 correlating with up-regulation of
EGFR from FaDu to A431 cells. High EGFR expression in A431
cells compared with FaDu cells agrees with previous studies [17].
Furthermore, in SCCs, the CCHCR1 immunostaining was
heterogeneous in atypic cells – many atypic cells were also devoid
of Ki67.
Figure 7. CCHCR1 mRNA expression in normal keratinocytes and SCC cell lines correlates with Ki67 expression. A) Ki67, EGFR, cyclin-
D1 and CCHCR1 gene expression profile of five normal epidermal KC and eight cutaneous SCC cell lines (heatmap). Signal values of the probe sets
were compared to the mean signal values of each probe set in KCs. The colouring is based on the log2 values of the change in the signal values. The
up-regulated genes are shown in red and down-regulated genes are shown in green. B) Correlation between CCHCR1 and Ki67 probe sets was
calculated between the signal values of one CCHCR1 and one Ki67 probe set in the HG-U133 Plus 3.0 array. Pearson’s correlation coefficient R=0.88.
C) CCHCR1 and D) Ki67 mRNA expression levels in the normal KCs and cutaneous SCC cell lines as measured by qRT-PCR (TaqMan). Expression levels
of CCHCR1 and Ki67 in the normal KCs and SCC cell lines were analyzed by qRT-PCR and corrected for the b-actin mRNA levels in the same samples. E)
Correlation between CCHCR1 and Ki67 probe sets was calculated between the signal values of CCHCR1 and Ki67 mRNA levels. Pearson’s correlation
coefficient R=0.46.
doi:10.1371/journal.pone.0006030.g007
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PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e6030Figure 8. Expression and regulation of CCHCR1, Ki67, and EGFR mRNA in HaCaT cells, its ras-transformed clones and SCC cell lines.
CCHCR1 (A), Ki67 (B), and EGFR (C) mRNA expression levels (TaqMan) in HaCaT cells after treatment with the tumor promoters OA and menadione.
CCHCR1 (D), Ki67 (E) and EGFR (F) mRNA expression in HaCaT, A5, II4, RT3, A431, and FaDu cells. The invasive cells II4 and FaDu and metastatic RT3
cells expressed less CCHCR1 (D) and Ki67 (E) than HaCaT and A5 cells. A431 cells (F) express EGFR mRNA clearly more than other cell lines. The ras-
transformed clones A5, II4, and RT3 and FaDu cells express EGFR less than HaCaT cells. Quantitative RT-PCR results are shown relative to mRNA levels
from corresponding control cells (assigned the value 1). Expression levels of CCHCR1, Ki67, and EGFR in HaCaT cells were normalized to the GAPDH
mRNA levels in the same samples. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0006030.g008
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PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e6030The tumor promoters OA and menadione downregulated the
expression of CCHCR1, Ki67, and EGFR mRNAs in HaCaT
cells. OA inhibits serine/threonine-specific protein phosphatases,
including protein phosphatases 1, 2A, and PP3 [18] and activates
cellular Erk1/2, JNK and p38 MAPK signaling pathways and AP-
1 transcription factors [19–21] in addition to activating Akt-1, a
pro-survival serine-threonine kinase [22]. Menadione inhibits
protein tyrosine phosphatases activating ErbB2 which is overex-
pressed in BCC and downregulated in SCC relative to normal
epidermis [23]. Interestingly, EGFR activity has been implicated
in OA-induced carcinogenesis and menadione-induced ErbB2
activation [24,25]. Furthermore, EGFR has been reported to
activate Erk1/2 and Akt in SCC [10].
Ultraviolet radiation is one of the most important factors
predisposing to skin cancer and is also known to activate EGFR
[9]. We have not detected significant changes in CCHCR1 mRNA
levels in HaCaT cells cultured for various periods after UVA/UVB
radiation (Suomela, Latonen and Saarialho-Kere, unpublished
Figure 9. Expression of CCHCR1, Ki67, and EGFR in HaCaT cell proliferation assay. A) Relative expression of CCHCR1 mRNA (as measured
by TaqMan) at different time points (from 24 h to 8 d) after releasing the cells from serum starvation and high density culturing. Expression of
CCHCR1 did not differ between confluent (control) cells and quiescent (starved) cells. Control cells expressed CCHCR1 2.5-fold more than proliferative
HaCaT cells (24–48 h, 3–4 d). As confluency was reattained (8 d), the expression of CCHCR1 increased to the level of the control cells. B) Correlation
between relative CCHCR1 and Ki67 expression levels. When CCHCR1 mRNA expression levels were compared to those of Ki67, a negative correlation
was seen, confirming the proliferative status of the HaCaT cells. C) EGFR mRNA expression correlated with CCHCR1 mRNA expression. D) Correlation
between CCHCR1 and Ki67 expression in the experiment with lower cell density. The negative correlation of CCHCR1 expression with Ki67 expression
was even more profound as relative CCHCR1 mRNA decreased near to zero in the two control cells. E) Correlation between CCHCR1 and EGFR
expression in the experiment with lower cell density. Here again, CCHCR1 expression correlated with EGFR expression. TaqMan PCR results are shown
relative to mRNA levels from corresponding control cells assigned the value 1. Expression levels of CCHCR1, Ki67, and EGFR in HaCaT cells were
normalized to the GAPDH mRNA levels in the same samples. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0006030.g009
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oxidative stress) on CCHCR1 mRNA expression either, although
also OA as well as menadione are known to induce the formation of
reactive oxygen species and lipid peroxidation on immortalized cell
lines [26,27], suggesting that oxidative stress was not involved in the
interaction of OA and CCHCR1.
Finally, we demonstrate that in HaCaT cells, CCHCR1
expression decreased with proliferation, in accordance with our
earlier reports [1,3,4]. After provoking proliferation in HaCaT
cells as described earlier [14], the more proliferative the non-
tumorigenic HaCaT cells were, the less CCHCR1 was expressed.
Interestingly, EGFR mRNA expression followed that of CCHCR1
mRNA expression rather than Ki67 expression, suggesting a
common up-stream effector in signaling pathways. We cannot,
however, in this setting exclude the effect of cell confluency alone
on CCHCR1 expression as it affects also the proliferation of
HaCaT cells.
Malignant transformation of psoriatic lesional KCs is very
uncommon despite of uncontrolled KC proliferation and co-
existence of chronic inflammation. The reason for protection from
cancer development remains unclear. Reduced AP-1 levels in
psoriatic KCs have been suggested as an explanation [28,29]. AP-
1 mediated pathway is also involved in EGFR activation leading to
KC hyperproliferation [5]. When the CCHCR1 transgenic risk
mice, with downregulated vitamin D receptor [30], were wounded
and PMA-treated, KC proliferation was reduced [3], suggesting
less active AP-1 or STAT3 signaling. Furthermore, vitamin D, a
drug used in the treatment of psoriasis, downregulates EGFR and
cyclin-D1 [31]. CCHCR1 has also been proposed to regulate
migration of the RNA polymerase II subunit 3 (RPB3) [32], that
activates the activating transcription factor 4 (ATF4 or CREB2)
[31] associating with growth arrest [34,35] and being able to form
heterodimers with members of the AP-1 family. The present study
implicates that CCHCR1, a candidate gene for psoriasis, has a
function in KC biology also in malignant transformation. Further
studies are needed to reveal the complex signaling system behind
the herein demonstrated possible connections with CCHCR1 and
EGFR network in KC proliferation and transformation.
In conclusion, CCHCR1 is upregulated in SCC in vivo and is
present in EGFR-positive cells. Its expression was not induced in
vitro in the most aggressive and metastatic SCC cell lines.
Ascending tumorigenicity and proliferative state downregulated
CCHCR1 mRNA in HaCaT cells, agreeing with our previous
results on CCHCR1 as an antiproliferative agent. Furthermore,
CCHCR1 and Ki67 expression correlated in SCC samples in vivo
and in human SCC cell lines by Affymetrix and TaqMan assay.
Previously, we could not observe correlation with CCHCR1 and
Ki67 in psoriasis lesions [4] nor in PMA-induced hyperprolifera-
tion of transgenic mouse skin [30], and analogously in the current
study, we found negative correlation in the proliferation assay of
benign HaCaT cells. Thus, in contrast to benign KC hyperpro-
liferation in psoriasis, Ki67 expression in vivo and in vitro
associated with CCHCR1 expression in malignant transformation.
We hypothesize that in psoriasis dysregulation of CCHCR1 may
lead to abnormal KC hyperproliferation [3], whereas it may
participate in regulating cell proliferation in the early stages of KC
transformation as well, but beyond a certain point in oncogenesis
CCHCR1 cannot control this phenomenon any longer.
Materials and Methods
Chemicals and materials
Cell culture media and fetal calf serum were from GIBCO
Invitrogen Life Technologies (Paisley, Scotland). Cytokines and
chemicals were from Calbiochem (La Jolla, CA), Invitrogen Life
Technologies, Merck (Darmstadt, Germany), R&D Systems
(Abingdon, UK), Roche Molecular Biochemicals (Indianapolis,
IN), and Sigma (St. Louis, MO). Reagents for real-time
quantitative PCR were from Applied Biosystems (Warrington,
UK).
Cell cultures
The immortalized human KC cell line HaCaT and its
subclones with increasing malignancy A5, II4, and RT3 as well
as A431 and FaDu SCC cell lines were cultured as described
earlier [31,36,37]. To study the regulation of CCHCR1
expression, HaCaT cells were plated on tissue culture plates and
allowed to reach 70–80% confluence. Then the cells were depleted
of serum overnight prior to stimulation with anisomycin (25 ng/
ml; 6, 24, and 48 h), menadione (10 mM; 6 h), OA (10 nM and
30 nM; 24 h), PMA (10 ng/ml, 25 ng/ml and 50 ng/ml; 24 h),
staurosporine (25 nM, 24 h), IL-6 (1 ng/ml, 20 ng/ml; 24 and
48 h), staphylococcal endotoxin B (0.1 ng/ml, 1 ng/ml, 10 ng/ml,
100 ng/ml; 24 and 48 h), and tamoxifen (50 nM, 100 nM,
1000 nM; 24 and 48 h) (all from Sigma). Activin A (18 ng/ml;
6, 24, and 48 h) was from R&D Systems (Minneapolis, MN) and
leptin (10 ng/ml, 100 ng/ml, 1000 ng/ml; 30 min, 60 min and
24 h) from Calbiochem. Cells were also stimulated by H2O2
(0.05 mM, 0.1 mM, 0.5 mM, 1.0 mM; 2 and 4 h). The cells were
lyzed and total RNA was extracted using RNeasy Mini-kit
(Qiagen, Chatsworth, CA) as instructed by the manufacturer.
Cells given fresh serum-free medium were used as controls. All
treatments were carried out in triplicate, and the results were
confirmed in at least two independent experiments.
Human cutaneous SCC cell lines (n=8) were established at the
time of operation from five primary and three metastatic SCCs
[38]. Cells were cultured in DMEM supplemented with 6 nmol/l
glutamine, nonessential amino acids, and 10% fetal calf serum
(FCS). Normal human epidermal KC cell lines (n=5) were
established from skin samples, and one NHEK cell lines was
purchased from PromoCell (Heidelberg, Germany). The cell lines
were cultured in Keratinocyte Basal MediumH 2, supplemented
with SingleQuotsH (Cambrex Bioscience; Walkersville, MD), as
previously described [39]. The biopsies for cell lines were
approved by the Joint Ethical Committee of the University of
Turku and Turku University Central Hospital. Participants gave
their informed consent, and the study was conducted according to
Declaration of Helsinki.
Quantitative Real-Time PCR (TaqMan RT-PCR)
cDNA synthesis and TaqMan RT-PCR for CCHCR1, EGFR,
Ki67, and GAPDH were performed as described earlier [1,40].
Reactions were performed with the Applied Biosystems 7500 Fast
Real-Time PCR System with standard protocol. Quantitative
PCR reactions to confirm microarray results were performed using
the ABI 7900HT real-time PCR machine (Applied Biosystems),
with each reaction containing 4 ng of reverse transcribed RNA in
a2 0 ml reaction. EGFR and Ki67 primers and probes were
purchased from Applied Biosystems (Hs01076092_ml and
Hs01032443_ml, respectively). The relative RNA levels in each
sample were determined by performing standard curves for all
target genes covering 0.1–10 ng of RNA. Each sample was run in
duplicate and b-actin was used as a control to normalize for
differences in the amount of total RNA in each sample.
Proliferation assays
Proliferation of HaCaT cells was assayed according to Pivarcsi
et al. [14]. Shortly, HaCaT cells were synchronized by culturing in
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bovine serum for five days after confluence was reached. The cells
were washed and medium replaced by serum-free DMEM. After
culturing for one week, cells were trypsinized, counted and their
viability determined by trypan blue staining. They were seeded
into 25-cm
2 culture flasks at a density of 5610
3 cells/cm
2 in 5%
FBS-DMEM to induce the proliferation. Samples for TaqMan
RT-PCR analysis were taken at different time points and the
experiment was repeated three times.
Differentiation assay
HaCaT keratinocytes were cultured in defined K-SFM (GIBCO
Invitrogen Life Technologies) medium of low calcium concentra-
tion (,1610
24 M). After five days, cells were trypsinized and
seeded onto 25-cm
2 culture flasks at a density of 1610
4 cells/cm
2
using the same medium as above except high calcium concentra-
tion (1.8610
23 M) to promote cell differentiation [41]. Samples
for TaqMan RT-PCR analysis were taken at different time points.
Tissue samples
Paraffin-embedded, formalin-fixed samples of human skin were
obtained from the Department of Dermatopathology, Skin and
Allergy Hospital, University of Helsinki, Finland and they were cut
at the thickness of 4 mm. To study CCHCR1 expression in
relation to tumorigenesis the following specimens were selected:
KA (n=18), AK (n=11), Bowen’s disease (n=21), SCCs (n=22,
of which grade I n=9, grade II n=6, grade III n=7), and BCCs
(n=15, of which morpheaform n=3, superficial n=3, nodular
n=9). The study was conducted in accordance to the Declaration
of Helsinki principles and use of anonymous archival samples
without written consent was approved by the corresponding
Ethical Review Board of Helsinki University Central Hospital,
Helsinki, Finland.
Immunohistochemistry
Immunostainings of tissue sections were performed using the
avidin-biotin-peroxidase complex method (Vectastain ABC Kit,
Vector Laboratories, Burlingame, CA, for CCHCR1 and cyclin-
D1; or StreptABComplex/HRP Duet (Mouse/Rabbit), DAKO,
A/S Glostrup, Denmark, no. K0492 for EGFR and Ki67).
Samples were immunostained using antibodies for Ki67 (Dako-
Cytomation, A/S Glostrup, Denmark), EGFR (Zymed Laborato-
ries, San Francisco, CA), cyclin-D1 (Thermo Fisher Scientific,
Fremont, CA), and CCHCR1 [1,4]. Sections were pretreated with
trypsin (10 mg/ml; CCHCR1, EGFR) or by microwaving in
citrate buffer (Ki67, cyclin-D1). Aminoethylcarbazole or diami-
nobenzidine were used as chromogenic substrates and hematox-
ylin as counterstain. Controls with preimmune sera or normal
rabbit immunoglobulin were used as negative controls.
Microarray analyses
Total RNA was extracted from cultured cells using TRIzol
reagent (Invitrogen; Carlsbad, CA) or using the Qiagen RNeasy
kit (Qiagen). Total RNA was reverse-transcribed and used as a
template for biotin-labeled cRNA. Samples were hybridized to
Affymetrix’s Human Genome U133 Plus 2.0 array, and the data
analyses were performed at the Microarray Centre of Turku
Centre for Biotechnology according to the manufacturer’s
protocol. Sequence specificity of Affymetrix probes was verified
by BLAST search. EGFR 211607_x_at and EGFR 210984_x_at
recognize all variants, EGFR 211551_at aberrant EGFR, EGFR
211550_at variant 4, EGFR 201984_s_at and EGFR 201983_s_at
variant 1, EGFR 1565484_x_at and EGFR 1565483_at variant 2.
CCHCR probes recognize all variants and MKi67 probes
recognize the same transcript.
Immunofluoresence staining of transfected cells
HaCaT cells were transiently transfected with the pCMV5-
CCHCR1 construct [4,42,30] using the FuGENE HD reagent
(Roche Diagnostics) according to the manufacturers’ instructions.
Cells were fixed with 4% paraformaldehyde-PBS solution
24 hours after transfection, washed with PBS and permeabilized
with 0.5% Triton-X100. Cells were immunostained with the
rabbit polyclonal antibody for CCHCR1 [4] and mouse
monoclonal antibody against the EGFR (Zymed laboratories,
Invitrogen immunodetection). Alexa Fluor 555-anti mouse and
Alexa Fluor 488-anti rabbit IgGs (Invitrogen) were used as
secondary antibodies. Cell nuclei were visualized with 49-6-
Diamidino-2-phenylindole staining.
Statistical analysis
Statistical significance of the differences in mRNA expression
levels in TaqMan analyses was calculated using the unequal, two-
tailed, odd t-test or using the non-parametric Mann-Whitney U
test. Correlation was calculated with Pearson’s correlation
coefficient.
Supporting Information
Figure S1 Expression of CCHCR1 in grade III SCC. CCHCR1
protein is expressed in proliferative cancer cells at the invasive
front of grade III SCC. Scale bar: 125 mm
Found at: doi:10.1371/journal.pone.0006030.s001 (4.00 MB TIF)
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